Summit Therapeutics plc Summit Therapeutics Plc : Director/Pdmr Shareholding

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
 
 
   Exercise of Share Options 
 
   Oxford, UK, and Cambridge, MA, US, 23 April 2018 - Summit Therapeutics 
plc (AIM: SUMM, NASDAQ: SMMT), announces the exercise by the following 
Non-Executive Directors of share options over the Company's ordinary 
shares of one penny nominal value granted under the Company's 2005 share 
option scheme. None of the new ordinary shares were sold by the 
Non-Executive Directors. The exercise of the options is in line with the 
stated intention of the Non-Executive Directors to advance the Company's 
objective of meeting best UK corporate governance practice that favours 
non-performance remuneration, such as restricted stock units. 
 
 
 
 
                                          Number of                    % of 
                             Number of   Outstanding                  Issued 
                             Exercised     Options     New Total      Share 
                              Options       held      Shareholding   Capital 
             Non-Executive 
Barry Price   Director           31,481          Nil       107,211       0.13% 
Stephen      Non-Executive 
 Davies       Director           17,500          Nil       602,481       0.74% 
 
 
   The admission of these new ordinary shares to trading on AIM is covered 
by the Company's existing block listing application. Following the 
exercise of these share options, the total number of options capable of 
vesting under the Company's 2005 and 2016 share option schemes is now 
10,009,284. 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014 (MAR). 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease, Duchenne 
muscular dystrophy, and the infectious disease, Clostridium difficile 
infection. Further information is available at www.summitplc.com and 
Summit can be followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)             Tel:    [phone] 
Erik Ostrowski / Michelle Avery (US office)                   [phone] 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:   [phone] 
Liam Murray / Tony Rawlinson 
 
 
   Notification of a Transaction pursuant to Article 19(1) of Regulation 
(EU) No. 596/2014 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
a)  Name                          Dr Barry Price 
2   Reason for the notification 
a)  Position / status             Non-Executive Director 
b)  Initial notification /        Initial notification 
    Amendment 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                          Summit Therapeutics plc 
b)  LEI                           213800NRW8AOMYMTBD89 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
a)  Description of the financial  Ordinary shares of 1 penny each 
    instrument, type of 
    instrument 
 
    Identification code           GB00BN40HZ01 
b)  Nature of the transactions    Exercise and hold of share options 
c)  Price(s) and volume(s)          Price(s)                          Volume(s) 
                                    65 pence (exercise price)         13,981 
                                     126 pence (exercise price)        17,500 
 
d)  Aggregated information 
    - Aggregated volume           31,481 ordinary shares 
    - Price                       GBP31,137.65 (being an average subscription price 
                                   of 98.9 pence per share) 
e)  Date of the transaction       23 April 2018 
f)  Place of the transaction      Outside a trading venue 
 
 
 
 
     Details of the person discharging managerial responsibilities/person 
1     closely associated 
a)   Name                            Professor Stephen Davies 
2    Reason for the notification 
a)   Position / status               Non-Executive Director 
     Initial notification / 
b)   Amendment                       Initial notification 
     Details of the issuer, emission allowance market participant, 
3     auction platform, auctioneer or auction monitor 
a)   Name                            Summit Therapeutics plc 
b)   LEI                             213800NRW8AOMYMTBD89 
     Details of the transaction(s): section to be repeated 
      for (i) each type of instrument; (ii) each type of 
      transaction; (iii) each date; and (iv) each place 
4     where transactions have been conducted 
     Description of the financial 
     instrument, type of 
a)   instrument                      Ordinary shares of 1 penny each 
 
     Identification code             GB00BN40HZ01 
b)   Nature of the transactions      Exercise and hold of share options 
c)   Price(s) and volume(s)           Price(s)                        Volume(s) 
   126 pence (exercise price)                                             17,500 
 
d)   Aggregated information 
 - Aggregated volume             N/A 
 - Price 
e)   Date of the transaction         23 April 2018 
f)   Place of the transaction        Outside a trading venue 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

April 23, 2018 12:05 ET (16:05 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.